Mankind Pharma Limited
₹2,488.75+₹27.55 (+1.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹91,284 Cr
- P/E
- 54.8x
- EV / EBITDA
- 34.3x
- Revenue
- ₹9,498 Cr
- Net margin
- 21.7%
- ROCE
- 23.4%
Price chart
Technical chartScreen technicals →+1.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -0.6%
- 3M
- -3.4%
- 6M
- +10.8%
- 1Y
- +1.8%
- 5Y
- +78.3%
52-week range
Day change +₹27.55 (+1.1%) from ₹2,461 to ₹2,489 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in MANKIND, bought on each weekday since 2023.
AI Summary
Indian StockStrengths1
- Healthy return on equity of 19.3%
Concerns1
- Negative free cash flow (₹9857 Cr)
Rule-based from financial data. Not advice.
About the company
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally.
Read moreShow less
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.
- Sector
- Healthcare
- Shares outstanding
- 41.2 Cr shares
- ISIN
- INE634S01028
- BSE code
- 543904
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹91,284 Cr
- P/E
- 54.8x
- P/B
- 5.9x
- EV / EBITDA
- 34.3x
- EV / Sales
- 10.5x
- P/S
- 10.6x
- Earnings yield
- 1.8%
- 52-week high
- ₹2,618.15
- 52-week low
- ₹1,922.45
Profitability
- Operating margin
- 26.3%
- Net margin
- 21.7%
- EBITDA margin
- 30.6%
- ROE
- 19.3%
- ROCE
- 23.4%
- ROA
- 16.3%
- Dividend payout
- 0.0%
- Tax rate
- 18.0%
- Other income, % of PBT
- 16.1%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹9,498 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.1%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 12.5%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹2,641 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 41.9%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 3.7%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 14.4%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,983 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 10.2%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹11.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.9%
Solvency and efficiency
- Current ratio
- 4.33
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- Debt / EBITDA
- 0.01
- Interest coverage
- 133.65
- Financial leverage
- 1.19
- CFO / Net profit
- 1.06
- Cash / Market cap
- 3.9%
- Cash per share
- ₹85.86
- Asset turnover
- 0.75
- Fixed asset turnover
- 2.43
- Capital intensity
- 0.41
- Debtor days
- 33 days
- Inventory turnover
- 2.28
- Cash conversion cycle
- 118 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹20 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹6,931 Cr |
| Sales | Operating profit | ₹2,567 Cr |
| Operating profit | Interest | ₹372 Cr |
| Operating profit | Depreciation | ₹378 Cr |
| Operating profit | Profit before tax | ₹1,817 Cr |
| Other income | Profit before tax | ₹550 Cr |
| Profit before tax | Tax and other | ₹422 Cr |
| Profit before tax | Net profit | ₹1,945 Cr |
Revenue and net profit
Revenue grew 10.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹5,530 Cr | ₹1,084 Cr |
| FY2022 | ₹7,486 Cr | ₹1,389 Cr |
| FY2023 | ₹8,127 Cr | ₹1,248 Cr |
| FY2024 | ₹8,629 Cr | ₹1,876 Cr |
| FY2025 | ₹9,498 Cr | ₹1,945 Cr |
Cash flows
FY2025: ₹2,322 Cr from operations, -₹9,857 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹1,022 Cr | -₹105 Cr |
| FY2022 | ₹821 Cr | -₹539 Cr |
| FY2023 | ₹1,799 Cr | ₹758 Cr |
| FY2024 | ₹1,983 Cr | ₹64 Cr |
| FY2025 | ₹2,322 Cr | -₹9,857 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹9,498 Cr+10.1%1Y
- Net profit
- ₹1,945 Cr+3.7%1Y
- Cash from operations
- ₹2,322 Cr
- Free cash flow
- -₹9,857 Cr-15,501.6%1Y
- Revenue CAGR, 5Y
- 12.5%
- EBITDA CAGR, 5Y
- 14.6%
- Net profit CAGR, 5Y
- 14.4%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹9,498 Cr | ₹2,567 Cr | — | ₹1,945 Cr | ₹2,322 Cr | -₹9,857 Cr | 13.3% | +10.1% | +3.7% |
Monthly returns
Month-by-month returns of MANKIND across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹23,828 Cr |
| Equity capital | ₹41 Cr |
| Reserves | ₹14,599 Cr |
| Borrowings | ₹7,254 Cr |
| Other liabilities | ₹1,934 Cr |
| Assets | ₹23,828 Cr |
| Fixed assets | ₹3,471 Cr |
| Capital work in progress | ₹207 Cr |
| Investments | ₹16,683 Cr |
| Other assets | ₹3,467 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
MANKIND trades at 54.8x earnings against a peer median of 52.6x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Mankind Pharma LimitedMANKINDthis company | ₹91,284 Cr | 54.8x | 5.9x | 19.3% | 34.3x |
| Cipla Ltd.CIPLA | ₹1.2 L Cr | 22.5x | 3.5x | 14.6% | 19.3x |
| Apollo Hospitals Enterprises Ltd.APOLLOHOSP | ₹1.1 L Cr | 75.0x | 11.3x | 13.1% | 54.4x |
| Max Healthcare Institute LimitedMAXHEALTH | ₹1.0 L Cr | 144.0x | 11.8x | 8.9% | 96.8x |
| Lupin LtdLUPIN | ₹99,475 Cr | 18.6x | 3.7x | 11.3% | 27.4x |
| Dr. Reddy's Laboratories Ltd.DRREDDY | ₹99,417 Cr | 18.4x | 3.2x | 17.9% | 14.3x |
| Zydus Lifesciences LimitedZYDUSLIFE | ₹90,637 Cr | 18.8x | 4.2x | 21.9% | 18.4x |
| Alkem Laboratories LimitedALKEM | ₹70,090 Cr | 31.4x | 5.1x | 16.6% | 33.0x |
| Fortis Healthcare LtdFORTIS | ₹68,497 Cr | 370.0x | 7.4x | 2.2% | 160.8x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
MANKIND since 1 January, against earlier years.
Historical volatility
MANKIND's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 25.0% |
| FY2022 | 25.0% |
| FY2023 | 21.0% |
| FY2024 | 26.0% |
| FY2025 | 27.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹9,498 Cr |
| Costs | |
| Interest | ₹372 Cr |
| Expenses | ₹6,930 Cr |
| Operating profitOperating Profit | ₹2,567 Cr |
| Other income and charges | |
| Profit before tax | ₹2,367 Cr |
| Tax | |
| Net profitNet Profit | ₹1,945 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹23,828 Cr |
| Equity capitalEquity Capital | ₹41 Cr |
| Reserves | ₹14,599 Cr |
| Borrowings | ₹7,254 Cr |
| Other liabilitiesOther Liabilities | ₹1,934 Cr |
| AssetsTotal Assets | ₹23,828 Cr |
| Fixed assetsFixed Assets | ₹3,471 Cr |
| Capital work in progressCWIP | ₹207 Cr |
| Investments | ₹16,683 Cr |
| Other assetsOther Assets | ₹3,467 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹2,322 Cr |
| Investing cash flowCash from Investing Activity | -₹12,179 Cr |
| Financing cash flowCash from Financing Activity | ₹9,845 Cr |
| Change in cashNet Cash Flow | -₹11 Cr |
Learn while you research
Academy chapters picked for Mankind Pharma Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 54.8, learn when high multiples are justified.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read